{"id":41331,"date":"2026-05-20T10:22:18","date_gmt":"2026-05-20T10:22:18","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/41331\/"},"modified":"2026-05-20T10:22:18","modified_gmt":"2026-05-20T10:22:18","slug":"astrazenecas-new-fda-wins-raise-questions-on-growth-and-valuation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/41331\/","title":{"rendered":"AstraZeneca\u2019s New FDA Wins Raise Questions On Growth And Valuation"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both neoadjuvant and adjuvant settings, based on two phase 3 studies.<\/p>\n

The FDA also approved Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for treatment-resistant hypertension.<\/p>\n

These decisions expand AstraZeneca\u2019s oncology and cardiovascular portfolios and introduce new treatment options in early breast cancer and uncontrolled hypertension.<\/p>\n

AstraZeneca (LSE:AZN) is adding two fresh approvals to an already high profile pipeline, with Enhertu and Baxfendy now cleared in the United States for new indications and patient groups. The stock trades around \u00a3137.1 and is up 34.5% over the past year and 86.9% over five years, illustrating how the market has responded over time to changes in its broader portfolio.<\/p>\n

For investors, these approvals broaden the set of products that could influence AstraZeneca\u2019s mix of oncology and cardiovascular revenue over the coming years. A central consideration will be how quickly physicians adopt Enhertu in early HER2-positive breast cancer and where Baxfendy fits into treatment-resistant hypertension alongside existing options.<\/p>\n

Stay updated on the most important news stories for AstraZeneca<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on AstraZeneca.<\/p>\n

\"LSE:AZN<\/a> LSE:AZN Earnings & Revenue Growth as at May 2026 <\/p>\n

4 things going right for AstraZeneca that this headline doesn’t cover.<\/a><\/p>\n

Investor Checklist Quick Assessment <\/p>\n

\u2705 Price vs Analyst Target: At \u00a3137.1, the stock trades about 17% below the \u00a3165.02 analyst price target.<\/p>\n

\u2705 Simply Wall St Valuation: Shares are flagged as trading 42.7% below estimated fair value, suggesting a valuation gap.<\/p>\n

\u274c Recent Momentum: The stock is down 9.3% over the past 30 days, so the price has recently been under pressure.<\/p>\n

There is only one way to know the right time to buy, sell or hold AstraZeneca. Head to Simply Wall St’s company report for the latest analysis of AstraZeneca’s Fair Value..<\/p>\n

Key Considerations <\/p>\n

\ud83d\udcca FDA approvals for Enhertu in early HER2-positive breast cancer and Baxfendy in uncontrolled hypertension expand AstraZeneca’s reach in oncology and cardiovascular treatments.<\/p>\n

\ud83d\udcca Watch how quickly Enhertu and Baxfendy are incorporated into treatment guidelines, alongside future updates on revenue and earnings that reflect their contribution.<\/p>\n

\u26a0\ufe0f AstraZeneca carries a high level of debt, so investors may want to see how new product cash flows support balance sheet strength over time.<\/p>\n

Dig Deeper <\/p>\n

For the full picture, including more risks and rewards, check out the complete AstraZeneca analysis. Alternatively, you can visit the community page for AstraZeneca<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include AZN.L<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":41332,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,5935,20684,20683,5758,20682],"class_list":["post-41331","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-breast-cancer","tag-fda-approval","tag-simply-wall-st","tag-stock-trades","tag-uncontrolled-hypertension"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/41331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=41331"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/41331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/41332"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=41331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=41331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=41331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}